Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Puff Puff Post

MARCH 10, 2020

” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial. Visit [link].

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Veriheal

JANUARY 11, 2023

Gaize is mastering the art of cannabis impairment detection. The Missoula, Montana-based company is gearing up for the launch of its first science-backed real-time cannabis impairment detection device. Studies on cannabis have shown that the plant may cause disorientation, sedation, lack of concentration, and impaired judgment.

Clinical Trials 97

Clinical Trials THC Data Safety 97

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 92

Clinical Trials Research and Development Therapy Policy 92

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. RYAH Group Inc.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Canna Care Docs

OCTOBER 3, 2023

As a devastating diagnosis, patients with a terminal illness must not only learn to cope with this information about their health but find restorative ways to alleviate the most common symptoms and effects. However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Eight studies were included, all of which are randomized controlled trials. 1.69, 95% CI [1.20–2.36])

Safety 52

Safety Cannabinoids Events Data 52

Veriheal

AUGUST 28, 2023

And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. ” Simply put, there is the expectation that ongoing and future clinical trials will further establish therapeutic potential in using psilocybin for OCD.

Treatment 56

Treatment Clinical Trials Therapy Research and Development 56

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

AUGUST 3, 2021

There are numerous risks and uncertainties that could cause actual results and Cybin’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Medicinal Marijuana Association

FEBRUARY 11, 2024

You may have heard whispers of cannabis being used to address a specific eye condition, but what does the research truly reveal about its effectiveness? The potential link between cannabis and glaucoma treatment is a topic of ongoing investigation, stirring both curiosity and caution within the medical community.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

The Cannigma

FEBRUARY 2, 2021

This article was originally published on Analytical Cannabis and appears here with permission. . In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

AUGUST 5, 2021

Although the overarching market is still relatively new, much like the cannabis boom a few years ago the psychedelics space is growing at an unprecedented rate. Thanks to the license, Filament will look to create the first-ever natural pharmaceutical grade extracts and put them into clinical trials in order to demonstrate safety and efficacy.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

PrestoDoctor

OCTOBER 11, 2023

For years, the use of cannabis has been a controversial topic. One area of research that has been gaining attention is the use of CBD-rich cannabis in treating the social symptoms of Autism Spectrum Disorder (ASD). One such area of focus is the use of CBD-rich cannabis. What is CBD?

CBD 52

CBD Research and Development Clinical Trials Treatment 52

The Cannigma

MARCH 7, 2022

Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . Of course, this plant is now known to be marijuana (or Type I cannabis), which is still commonly used for sleep and analgesia today. The best online schools for medical cannabis training.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

The Cannigma

AUGUST 31, 2021

Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. People want to trust their doctors, but doctors need knowledge. We have a ways to go,” Tan said.

Education 101

Education Clinical Trials Medicine Policy 101

Cannabis Law Report

JANUARY 12, 2022

This level of understanding can inform best practices, improve outcomes, and contribute to sensible policy-making both in Oregon and beyond. Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. Clinical trial information: NCT03276572 ( [link] ). Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

JULY 28, 2021

More information about the organization is available at [link]. Reporting to the Regulatory Affairs Manager, the RPS supports functions related to tracking regulatory information and document styling and publishing in eCTD format for regulatory submissions. MAPS PBC is committed to the evolution of psychedelic healing modalities.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

Cannabis Law Report

AUGUST 12, 2021

Phase IIb clinical trial of COMP360 psilocybin therapy for TRD close to completion. Danielle Schlosser PhD appointed Senior Vice-President, Clinical Innovation, to lead therapist research and training, bringing her clinical experience in behavioural health and expertise in digital health innovation. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

WeedAdvisor

JULY 4, 2019

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety. A Vicious Circle. .

DEA 111

DEA Research and Development Clinical Trials Cultivation 111

Veriheal

APRIL 11, 2022

Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Fortunately, the U.S. territories.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

MARCH 1, 2022

Focus will be on IND/CTA filings and associated interactions, and may include safety reports, protocols, information amendments, responses to requests for information, IND Annual Reports/DSURs, and new investigator amendments. Knowledge of Canadian, Australian and New Zealand clinical trial regulations and procedures is a plus.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

Cannabis Law Report

JULY 30, 2019

Cannabis-based products will be allowed to bypass usual processes required for medicines in New Zealand and go directly onto the market without any proof of safety or effectiveness. This unprecedented proposal is contained in the government’s consultation document on giving greater access to medicinal cannabis.

Medicine 40

Medicine Clinical Trials Safety Access 40

Cannabis Law Report

JUNE 17, 2021

Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. More information can be found at www.dsm.com/venturing. Readers should not place undue reliance on the forward-looking statements and information contained in this news release.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Otherside Farms

JANUARY 25, 2019

“This meta-analysis of pre-clinical stroke studies provides valuable information on the existing, and importantly, missing data on the use of cannabinoids as a potential treatment for stroke patients. The findings have identified the potential for cannabinoids to reduce brain damage caused by stroke.

Clinical Trials 74

Clinical Trials Marijuana Cannabinoids Data 74

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. Tim Moynahan the company chairman stated that “Patients in the MMJ International holdings clinical trials will receiv e gelatin capsules containing THC and CBD daily.”.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

JULY 7, 2021

We remain encouraged as we continue our evaluations of MYMD-1 for efficacy and safety – especially as studies continue to suggest we may be able to address many of the concerns that are associated with the current drugs on the market today in these disease areas.”. For more information, visit www.mymd.com. Eurofins is testing for life.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

OCTOBER 13, 2021

Certain statements in this press release constitute forward-looking information. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Vigorous scientific research and clinical trials are needed. Cautionary Notes and Forward-Looking Statements.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

Cannabis Law Report

OCTOBER 2, 2021

Focus will be on IND/CTA filings and associated interactions, and may include safety reports, protocols, information amendments, responses to requests for information, IND Annual Reports/DSURs, and new investigator amendments. Knowledge of Canadian, Australian and New Zealand clinical trial regulations and procedures is a plus.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients.

Research and Development 108

Research and Development Data THC Clinical Trials 108